In this free webinar, learn about integrated pharmacology evaluations for target protein degradation (TPD) drug discovery. Attendees will gain insight into high-quality in vitro profiling via multi-technology integration. The featured speakers will discuss synthesis strategies for complex TPD molecules, including chiral center control and E3 ligand stability. The speakers will also share case studies on rapid synthesis of PROTACs and molecular glues.
TORONTO, June 9, 2025 /PRNewswire-PRWeb/ -- Target protein degradation (TPD) has emerged as an innovative "event-driven" therapeutic approach, overcoming the limitations of traditional small-molecule drugs by enabling the targeting of "undruggable" proteins with high potency and selectivity.
It offers a significant advantage by targeting these proteins at low doses, thus bringing new hope for clinical treatment. Molecular glues and proteolysis-targeting chimeras (PROTACs) have emerged as rapidly evolving molecules in the TPD field; however, their complex mechanisms introduce significant hurdles in preclinical drug discovery.
The synthesis of TPD molecules, particularly PROTACs, is highly complex due to their large molecular weight and intricate structures. This demands advanced synthetic strategies and the availability of a comprehensive E3 ligand library to achieve precise molecular assembly. Moreover, the in vitro evaluation of degraders relies on robust high-throughput screening methods and the capability to comprehensively profile compounds to ensure accurate assessment of their pharmacological effects. A novel approach leverages these capabilities to drive TPD drug discovery.
Register for this webinar today to explore insights into TPD drug discovery and solutions for these challenges.
Join experts from BioDuro, Yanchun Guo, PhD, Associate Director of Discovery; and Xingao Peng, PhD, Senior Director of Medicinal Chemistry, for the live webinar on Monday, June 23, 2025, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Fueling Target Protein Degradation Drug Discovery: In Vitro Evaluation and Synthesis Strategies.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], www.xtalks.com
SOURCE Xtalks
Share this article